Prostate Cancer Clinical Trials in Las Vegas, NV

View the best 10 prostate cancer medical studies in Las Vegas, Nevada. Access promising new therapies by applying to a Las Vegas-based Prostate Cancer clinical trial.

Trials in Las Vegas, Nevada

Here are the top 10 medical studies for prostate cancer in Las Vegas, Nevada

Michael Bask Gill, B Sc

Last Reviewed: December 31st, 2024

Apalutamide

Recruiting2 awardsPhase 3

This trial is testing whether adding apalutamide to the standard treatment of surgery and radiation therapy can improve outcomes for patients with lymph node positive prostate cancer.

Docetaxel +1 More

Cytotoxic Chemotherapy Agent

Recruiting2 awardsPhase 3

This trial is comparing the efficacy of adding Radium-223 to Docetaxel chemotherapy versus Docetaxel chemotherapy alone in men with metastatic hormone-refractory prostate cancer.

Abiraterone acetate +2 More

Hormone Therapy

Recruiting2 awardsPhase 3

This trial is testing a new drug called opevesostat for advanced prostate cancer patients who don't respond to usual care. The drug aims to stop the cancer from growing and spreading, potentially helping patients live longer.

LHRH Analogue +3 More

Hormone Therapy

Recruiting2 awardsPhase 3

This trial is testing whether two different drugs can extend the time before cancer progresses in men with recurrent prostate cancer.

XmAb20717

Monoclonal Antibodies

Recruiting1 awardPhase 2

This trial will study the safety and effectiveness of XmAb20717 as a treatment for patients with metastatic prostate cancer who have been previously treated with other cancer therapies.

Apalutamide +1 More

Antiandrogen

Recruiting1 awardPhase 3

This trial will study whether the addition of apalutamide to androgen deprivation therapy (ADT) can improve outcomes for men with metastatic hormone-sensitive prostate cancer (mHSPC).

Recombinant EphB4-HSA Fusion Protein +1 More

Recruiting1 awardPhase 2

This trial is testing a new cancer treatment that uses a fusion protein and an anti-PD1 antibody. There will be four cohorts of patients with different types of cancer, all of whom have not responded well to other treatments.

XL092

Recruiting1 awardPhase 1

This trial is testing a new drug called XL092 alone and with other cancer drugs in patients with advanced solid tumors. The goal is to see if these treatments can safely stop or slow tumor growth and help the immune system fight cancer more effectively.

Nivolumab +1 More

Checkpoint Inhibitor

Recruiting1 awardPhase 2

This trial is studying nivolumab and ipilimumab in treating patients with rare tumors.

TAK-700 +1 More

Androgen Synthesis Inhibitor

Recruiting2 awardsPhase 3

This trial is testing if a new drug called TAK-700 helps people with prostate cancer live longer than another drug called bicalutamide when used with ADT.

Popular Filters

Phase 3 Trials

Antiandrogen

Apalutamide + ADT for Prostate Cancer

Recruiting1 awardPhase 3

Las Vegas, Nevada

This trial will study whether the addition of apalutamide to androgen deprivation therapy (ADT) can improve outcomes for men with metastatic hormone-sensitive prostate cancer (mHSPC).

Corticosteroid

Apalutamide + Abiraterone Acetate + Prednisone for Prostate Cancer

Recruiting1 awardPhase 3

Las Vegas, Nevada

This trial tests apalutamide added to a standard treatment for advanced prostate cancer. It targets patients whose cancer has spread and who haven't had chemotherapy. The treatment works by blocking and lowering male hormones that help cancer grow. Apalutamide has shown efficacy in treating different stages of prostate cancer.

Antiandrogen

Apalutamide for Castration-Resistant Prostate Cancer

Recruiting1 awardPhase 3

Las Vegas, Nevada

This trial will test whether apalutamide can help treat prostate cancer that is not responding to hormone therapy and has not spread.

Androgen Synthesis Inhibitor

TAK-700 vs. Bicalutamide for Prostate Cancer

Recruiting2 awardsPhase 3

Loma Linda, California

This trial is testing if a new drug called TAK-700 helps people with prostate cancer live longer than another drug called bicalutamide when used with ADT.

Radiation Therapy

Radiation Therapy + Androgen Deprivation for Prostate Cancer

Recruiting2 awardsPhase 3

Orange, California

This study is evaluating whether radiation therapy is more effective than short-term androgen deprivation therapy for prostate cancer.

Chemotherapy + Hormone Therapy With Surgery for Prostate Cancer

Recruiting4 awardsPhase 3

Los Angeles, California

This trial is comparing docetaxel given before surgery to surgery alone in treating patients with high-risk localized prostate cancer to see if it is more effective.

Trials With No Placebo

Checkpoint Inhibitor

Nivolumab + Ipilimumab for Rare Cancers

Recruiting1 awardPhase 2

Kingman, Arizona

This trial is studying nivolumab and ipilimumab in treating patients with rare tumors.

sEphB4-HSA + Pembrolizumab for Cancer

Recruiting1 awardPhase 2

Las Vegas, Nevada

This trial is testing a new cancer treatment that uses a fusion protein and an anti-PD1 antibody. There will be four cohorts of patients with different types of cancer, all of whom have not responded well to other treatments.

Kinase Inhibitor

Targeted Therapy for Cancer

Recruiting1 awardPhase 2

Kingman, Arizona

This trial uses genomic testing to direct cancer treatment. Patients with cancer that has progressed after standard treatment or for which there is no agreed-upon treatment may benefit.

Androgen Synthesis Inhibitor

TAK-700 vs. Bicalutamide for Prostate Cancer

Recruiting2 awardsPhase 3

Loma Linda, California

This trial is testing if a new drug called TAK-700 helps people with prostate cancer live longer than another drug called bicalutamide when used with ADT.

Hormone Therapy

Bicalutamide + MK2206 for Prostate Cancer

Recruiting1 awardPhase 2

Palo Alto, California

This trial is testing bicalutamide with or without Akt inhibitor MK2206 to see if it's effective in treating prostate cancer in patients who have been treated before.

Radiation Therapy

Radiation Therapy + Androgen Deprivation for Prostate Cancer

Recruiting2 awardsPhase 3

Orange, California

This study is evaluating whether radiation therapy is more effective than short-term androgen deprivation therapy for prostate cancer.

View More Related Trials

External Beam Radiation Therapy

External Beam Radiation Therapy +3 More

LHRH Analogue +3 More

Carboplatin +7 More

INKmune

XL092

Vudalimab (XmAb20717)

XmAb20717

Rucaparib camsylate +1 More

Atezolizumab +1 More

Pembrolizumab +2 More

Apalutamide

Carboplatin +1 More

Nivolumab +2 More

Abiraterone acetate +2 More

AZD5305 +1 More

View more prostate-cancer clinical trials las-vegas

See more medical studies focusing on prostate-cancer las-vegas

Frequently Asked Questions

Do I need insurance to participate in a trial?

Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).

Is there any support for travel costs?

Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.

Will I know what medication I am taking?

This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.

How long do clinical trials last?

Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.

Do you verify all the trials on your website?

All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.

How quickly will I hear back from a clinical trial?

Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.